Shares in Glanbia jumped 9 per cent on Wednesday after a strong trading update, though the more intriguing narrative sits beyond whey protein and into the slow-burn impact of weight-loss drugs.
GLP-1 therapies suppress appetite, and exploding demand for them has left much of the food industry scanning for casualties.
However, Barclays analysts think Glanbia may instead be a beneficiary of sorts.
Growth in the first quarter came from volumes rather than pricing, with obvious strength in performance nutrition and health and nutrition. In other words, consumers are buying a lot more, with that demand being concentrated in protein, fitness and “active lifestyle” products.
READ MORE
That is the supposed GLP-1 twist. If people eat less overall, they may also become more selective, tilting towards protein-rich and functional foods and away from conventional snacking.
Glanbia’s flagship Optimum Nutrition brand sits comfortably in that niche. Any caveats? There are a few.
Glanbia’s earnings beat may have been flattered by promotional demand in January and February – “New Year, New You”, and all that.
Some investors also question whether there was a pre-buy effect in advance of April’s price increases. Barclays is positive on that front, saying management commentary suggested that any pre-buy impact was “limited, pointing to a clear underlying beat”.
Still, that won’t become clear for some time, with April’s price rises set to be a better test of underlying demand.
Nevertheless, with the shares already up 35 per cent in 2026, investors are backing Glanbia as a rare food company that might benefit from people eating less.
